Information  X 
Enter a valid email address

Bioventix Plc (BVXP)

  Print      Mail a friend

Monday 14 November, 2016

Bioventix Plc

Notice of AGM

Bioventix plc

(“Bioventix” or the “Company”)

Notice of AGM and Posting of Annual Report

Bioventix plc (AIM: BVXP) announces that its Annual General Meeting will be held at The Winchester Suite, Farnham Castle, Farnham, Surrey, GU9 0AG at 2.00 p.m. on Wednesday 7 December 2016.

Copies of the 2016 Annual Report and the Notice of the Annual General Meeting have been sent to shareholders and are also available on the Company's website at

For further information please contact:

Bioventix plc
Peter Harrison

Chief Executive Officer
Tel: 01252 728 001
finnCap Ltd
Geoff Nash/Simon Hicks
Steve Norcross

Corporate Finance
Corporate Broking
Tel: 020 7220 0500

About Bioventix plc:

Bioventix ( specialises in the development and commercial supply of high-affinity monoclonal antibodies with a primary focus on their application in clinical diagnostics, such as in automated immunoassays used in blood testing. The antibodies created at Bioventix are generated in sheep and are of particular benefit where the target is present at low concentration and where conventional monoclonal or polyclonal antibodies have failed to produce a suitable reagent. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. Bioventix currently supplies antibody products and services to the majority of multinational clinical diagnostics companies. Bioventix is based in Farnham, UK and its shares are traded on AIM under the symbol BVXP.

a d v e r t i s e m e n t